Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Stanford researchers have developed chemically modified AAV vectors through an unnatural amino acid substitution on the capsid surface for post-production vector engineering through biorthogonal copper-free click chemistry.